ReviewBiochemical Society transactions2026
Genes, fuel, and fate in lung cancer.
Review in Biochemical Society transactions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cellular plasticity is a central feature of malignant progression, allowing tumour cells to change identity during tumour evolution, therapeutic adaptation, and metastatic dissemination. This issue is especially acute in lung cancer, where the respiratory epithelium is intrinsically permissive to cell-state change. Genetic lesions, chromatin regulation, and metabolic adaptation are often framed as parallel determinants of lineage plasticity. Emerging evidence instead points to functional coupling across these layers. Oncogenic alterations can weaken lineage fidelity and open alternative trajectories, chromatin regulators can stabilise transitional states and enforce new transcriptional programmes, and metabolic rewiring can supply the biochemical conditions required for these states to emerge and persist. Microenvironmental cues further influence which trajectories are selected and maintained. Here, we discuss the genetic, epigenetic, and metabolic determinants of lineage plasticity in lung cancer, focusing on the points at which they intersect. We propose that plasticity is most usefully understood as a coupled regulatory state, arising from the interaction between oncogenic context, chromatin control, and metabolic support. Defining how these dependencies arise and become functionally coupled within high-plasticity transitional states should help identify points at which lineage switching can be intercepted before alternative lineage programmes are stabilised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.